CryoPort (CYRX) Expected to Announce Quarterly Earnings on Tuesday

CryoPort (NASDAQ:CYRX) is expected to issue its Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $42.9240 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 5:00 PM ET.

CryoPort Price Performance

Shares of NASDAQ CYRX opened at $8.42 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. CryoPort has a one year low of $4.58 and a one year high of $11.45. The firm has a market capitalization of $421.59 million, a P/E ratio of 7.20 and a beta of 1.66. The company’s fifty day moving average is $9.57 and its two-hundred day moving average is $9.41.

Analyst Ratings Changes

CYRX has been the topic of a number of research analyst reports. UBS Group boosted their price objective on shares of CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Needham & Company LLC lifted their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.83.

Insider Activity at CryoPort

In other news, Director Ramkumar Mandalam sold 11,570 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares of the company’s stock, valued at $806,772.42. This trade represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

Large investors have recently bought and sold shares of the stock. UBS Group AG increased its position in CryoPort by 112.7% during the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares in the last quarter. Millennium Management LLC boosted its stake in shares of CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock valued at $31,150,000 after acquiring an additional 623,896 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of CryoPort by 283.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock valued at $4,970,000 after acquiring an additional 387,440 shares during the last quarter. Mak Capital One LLC increased its position in CryoPort by 46.6% during the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock worth $11,513,000 after purchasing an additional 381,063 shares in the last quarter. Finally, Empire Financial Management Company LLC raised its stake in CryoPort by 141.8% in the 4th quarter. Empire Financial Management Company LLC now owns 403,861 shares of the company’s stock valued at $3,877,000 after purchasing an additional 236,861 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.